SCHEDULE: Indaptus Co-CEO Lazar Sells Major Stake, Steps Down

David E. Lazar, co-Chief Executive Officer of Indaptus Therapeutics, Inc., sold a significant portion of his preferred stock holdings for $11.2 million and resigned from his co-CEO role, while remaining on the Board of Directors.

Summary

• David E. Lazar sold 700,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock and 196,800 shares of Series AA Convertible Non-Redeemable Preferred Stock in Indaptus Therapeutics, Inc.
• The sale was made to Yun Yao (Lead Purchaser) and other purchasers for an aggregate purchase price of $11,200,000.
• The transaction closed on March 23, 2026.
• Lazar resigned as co-Chief Executive Officer of Indaptus Therapeutics, Inc. but will remain a member of the Issuer's Board of Directors.
• Following the sale, Lazar retains 103,200 shares of Series AA Preferred Stock, which are convertible into an aggregate of 2,064,000 shares of the Issuer's common stock.
• Lazar's beneficial ownership, as reported on the Schedule 13D/A, is approximately 47.93% of the common stock, calculated assuming conversion of only his retained shares and that the purchasers have not exercised their acquired preferred stock.
• Following the full conversion of all preferred stock (including those sold), Lazar's ownership will be approximately 1.82%.
• A 5% holdback amount, equal to $560,000, from the purchase price is held in escrow for a six-month term (subject to extension for any outstanding claims) to cover potential losses or liabilities.
• The purchasers have agreed to cause Indaptus Therapeutics, Inc. to include the common stock underlying Lazar's retained Series AA Preferred Stock in a resale registration statement to be filed by the Issuer within 30 days of the closing.
• In connection with the closing, two current directors of the Issuer resigned, leaving a total of seven directors on the Board.
• The Standby Equity Purchase Agreement (YA II PN SEPA) dated February 12, 2025, between Indaptus Therapeutics, Inc. and YA II PN LTD. was terminated.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development due to the significant reduction in a key insider's stake and the CEO's resignation, which could signal leadership instability or a lack of long-term commitment, despite the removal of a dilutive financing agreement.

Positives

• The termination of the YA II PN SEPA removes a potential dilutive financing agreement for Indaptus Therapeutics, Inc., which could be favorable for existing shareholders.
• The agreement includes a commitment from purchasers to facilitate a resale registration statement for Lazar's retained shares, providing a clear path for future liquidity for these shares.

Negatives

• The resignation of a co-Chief Executive Officer, especially one with a significant prior stake, could raise questions about leadership stability and future strategic direction of Indaptus Therapeutics, Inc.
• A substantial reduction in a key insider's ownership stake (from a potential 96.2% to 1.82% fully diluted) might be perceived negatively by the market, potentially signaling a lack of long-term conviction.
• The 5% holdback amount ($560,000) in escrow indicates potential liabilities or unresolved issues that could lead to future claims against the seller.

Risks

• Litigation Risk: The agreement includes indemnification clauses for losses arising from breaches of representations/warranties, undisclosed liabilities, or third-party claims prior to the closing date, indicating potential for future legal disputes.
• Undisclosed Liabilities: Seller's representations regarding liabilities are 'to Seller's Knowledge,' and the holdback amount is specifically for undisclosed liabilities or claims existing as of the closing date, suggesting a risk of unknown financial obligations for the company.
• Nasdaq Listing Compliance: The agreement emphasizes the need for Indaptus Therapeutics, Inc. to remain compliant with Nasdaq listing standards, including minimum bid price, market value, and corporate governance, implying a potential risk of non-compliance or delisting if these conditions are not met.
• Stockholder Approvals: Conversion of preferred stock into common stock is subject to stockholder approvals for increasing authorized shares and the conversion itself, posing a risk if these approvals are not obtained.
• Material Adverse Effect: The agreement includes conditions related to the absence of a 'Material Adverse Effect' on the company's business, assets, liabilities, results of operations, or financial condition, highlighting the ongoing risk of such events.

Future Outlook

Purchasers have agreed to cause Indaptus Therapeutics, Inc. to include the common stock underlying David E. Lazar's retained Series AA Preferred Stock in a resale registration statement to be filed within 30 days of the closing, providing a future liquidity path for these shares. The company is expected to continue complying with Nasdaq listing standards and SEC reporting obligations.

Management Comments

• David E. Lazar has resigned as co-Chief Executive Officer of the Issuer.
• David E. Lazar will remain a member of the Issuer's Board of Directors.

Industry Context

StockSavvy.ai notes that a significant insider sale and CEO resignation, even with board retention, can signal a shift in strategic direction or a lack of confidence in the company's near-term operational execution, particularly in the volatile biotechnology sector. The termination of a standby equity purchase agreement, however, could be viewed positively as it removes a potential source of future dilution, aligning with a trend of companies seeking less dilutive financing options.

Management Changes

Corporate Governance

Legal Proceedings

• The agreement includes indemnification for losses arising from third-party claims, governmental authority inquiries, or proceedings relating to events, facts, or circumstances occurring on or prior to the Closing Date.
• Seller represents that, to his knowledge, there are no actions pending or threatened in writing by or against the Issuer or affecting its properties, at law or in equity, before any court or governmental agency.

Related Party Transactions

• Sale of preferred stock by David E. Lazar (an officer and director) to Yun Yao and other purchasers for $11,200,000.
• The agreement states that, except for arms-length transactions in the ordinary course of business and as disclosed, no Related Party of Issuer is presently a party to any transaction with Issuer (other than for services as Issuer employees or consultants).

Stakeholder Impact

• Shareholders: Potential for increased volatility due to significant insider sale and CEO change. Future dilution risk from conversion of preferred shares remains, though the termination of YA II PN SEPA reduces one source. Registration rights for Lazar's retained shares could lead to future selling pressure.
• Management/Employees: Resignation of co-CEO may lead to leadership restructuring and potential shifts in strategic priorities.
• Creditors: The 5% holdback amount in escrow provides some protection against undisclosed liabilities existing at closing, potentially reducing risk for creditors.

Next Steps

• Indaptus Therapeutics, Inc. to file a resale registration statement for David E. Lazar's retained Series AA Preferred Stock within 30 days of the closing.
• Resolution of any claims against the 5% holdback amount in escrow, with release to the seller on the Holdback Release Date (approximately September 17, 2026).
• Ongoing compliance by Indaptus Therapeutics, Inc. with Nasdaq listing standards and SEC reporting obligations.

Key Dates

Recommendation

The significant reduction in a key insider's ownership stake, coupled with the co-CEO's resignation, signals a potential loss of confidence or a strategic pivot away from the company by a major stakeholder. While the termination of a dilutive financing agreement is positive, the overall sentiment from this insider transaction is negative, suggesting potential future challenges or a lack of strong conviction from a former leader. Investors should consider reducing exposure given these developments.

Keywords

Indaptus Therapeutics, David E. Lazar, Preferred Stock Sale, CEO Resignation, Schedule 13D, SEC Filing, Corporate Governance, Stock Ownership, Yun Yao, Securities Purchase Agreement, Biotechnology, Pharmaceuticals